ライフサイエンスコーパス: PPV

1 PPV and MFI were correlated with the endothelial activat

2 PPV improved when AH was the primary versus a secondary

3 PPV increased to 89% (95% CI 73%-96%) when ERCC1-SNP was

4 PPV was 98% (56 of 57 lesions) to 100% (60 of 60 lesions

5 PPV with secondary IOL placement is safe and effective,

6 PPVs of >0.998 and NPVs of >0.999 were obtained for all

7 .61) and destroyed mucosal folds (NPV, 1.00; PPV, 0.62) had a high NPV but a low PPV.

8 cularis: sensitivity, 2%; specificity, 100%; PPV, 100%; NPV, 85%).

9 ce in success rates between repeat PR (63%), PPV (76%), and SB+PPV (88%).

10 Overall classification accuracy was 87.7% (PPV 0.92, NPV 0.9, specificity 0.9, sensitivity 0.92).

11 71%; sensitivity, 36.4%; specificity, 92.8%; PPV, 76.2%; and NPV, 69.6%.

12 ivity, 91.9%; specificity, 74.0%; AUC, 0.83; PPV, 82.8%).

13 CI, 65-84]; specificity, 76 [95% CI, 65-84]; PPV, 60 [95% CI, 46-74]; and NPV, 94 [95% CI, 85-98]).

14 e algorithm achieved 90% specificity and 85% PPV for MSA and 94% specificity and 94% PPV for PSP.

15 Segment length of 10 cm or less (NPV, 0.85; PPV, 0.61) and destroyed mucosal folds (NPV, 1.00; PPV,

16 CI, 67-85]; specificity, 73 [95% CI, 66-85]; PPV, 56 [95% CI, 47-65]; and NPV, 87 [95% CI, 81-92]).

17 vity of 41% and 67%, NPV of 85% and 85%-86%, PPV of 18% and 35%-36%, and AUC of 0.54-0.58 and 0.69-0.

18 nsitivity and 96.9% specificity with a 90.9% PPV and a 99.2% NPV.

19 dation (PPV2), 27.5% (95% CI: 27.1%, 27.9%); PPV of biopsies performed (PPV3), 30.4% (95% CI: 29.9%,

20 85% PPV for MSA and 94% specificity and 94% PPV for PSP.

21 ivity, 91.4%; specificity, 96.0%; AUC, 0.94; PPV, 67.3%).

22 T and sIgE results at age 4 years with a 95% PPV for persistent peanut allergy are an SPT response of

23 ses and sIgE levels at age 1 year with a 95% PPV for persistent peanut allergy are an SPT-induced res

24 fined by clinical history of reactivity, 95% PPV or challenge, and IL13 genotyping was performed.

25 ith 89% sensitivity, 87% specificity and 97% PPV.

26 range, 69%-79%; specificity range, 54%-97%; PPV range, 52%-95%; NPV range, 79%-80%; herpes simplex v

27 rations: sensitivity, 20%; specificity, 98%; PPV, 88%; NPV, 57%; trichomoniasis, colpitis macularis:

28 range, 0%-100%; specificity range, 91%-99%; PPV range, 0%-3.6%; negative predictive value [NPV] rang

29 from 0% to 100%, and 11 uveitis codes had a PPV exceeding 80%.

30 oved sensitivity to 0.77 at the expense of a PPV of 0.64.

31 with 96.3% sensitivity, 78.1% specificity, a PPV of 89.6%, and a NPV of 91.5%.

32 y one of the 207 IMLNs was malignant, with a PPV of 0.005 (95% CI: 0.000, 0.027).

33 eoxyglucose-avid IMLNs was malignant, with a PPV of 0.083 (95% CI: 0.002, 0.385).

34 With a PPV of 0.9, these algorithms had associated sensitivitie

35 entified patients with celiac disease with a PPV of 0.988 and an NPV of 0.934; the TTG-DGL procedure

36 entified patients with celiac disease with a PPV of 0.988 and an NPV of 0.958.

37 The system classified polyps with a PPV of 89.6%, and a NPV of 91.5%, and in a shorter time

38 hildren with celiac disease (n = 399) with a PPV of 99.75 (95% confidence interval [CI], 98.61-99.99)

39 ate infected cells (specificity of 92.3% and PPV of 33.3%), but was hampered by technical failures.

40 on AAML0531, had a sensitivity of 78.3% and PPV of 98.1%.

41 iology data had high sensitivity (92.3%) and PPV (97.3%).

42 74.2% to 95.8% (reference method 93.8%), and PPV from 82.2% to 96.4% (reference method 99.6%).

43 US had a sensitivity of 70%, NPV of 84%, and PPV of 56% for the detection of ALN disease.

44 % to 100%; specificity, from 78% to 94%; and PPV, from 3% to 33% (3 studies).

45 Specificity (range, 90%-95%) and PPV (range, 63%-75%) appeared better than questionnaires

46 d from 1% to 99% (reference method 98%), and PPV from 8% to 100% (reference method 100%), when testin

47 in the affected segment showed high NPV and PPV (0.95 and 0.93, respectively).

48 1), PPV of biopsy recommendation (PPV2), and PPV of biopsies performed (PPV3) of digital mammography

49 indow) were 7.4% and 1.3%, respectively, and PPV was 1.8% for the presence of any of these predictors

50 s, but even with 11 samples, sensitivity and PPV did not exceed 0.36.

51 The sensitivity and PPV for bisphosphonate use were both 80% (95% confidence

52 ing provides high per-lesion sensitivity and PPV for preoperative malignant liver lesion detection ov

53 The high sensitivity and PPV of PHIS microbiology data suggest that using externa

54 amples, among males, yielded sensitivity and PPV values >/= 0.75 for the high and low tertiles, but,

55 Per-lesion sensitivity and PPV were calculated.

56 accuracy was similarly high (specificity and PPV > 90%) for parkinsonian subjects with short symptom

57 FDG PET/CT demonstrates high specificity and PPV for detecting distant metastasis in cervical and end

58 of imaging provides improved specificity and PPV for the detection of metastases and should be consid

59 For central readers, the specificity and PPV of PET/CT detection of cervical and endometrial canc

60 threshold that also has high specificity and PPV, and could be used as a screening tool in specialty

61 y records, the sensitivity, specificity, and PPV for self-reported use of statins, beta-blockers, and

62 s that included diagnosis codes for ascites (PPV 75%; 95% CI 63-86%), cirrhosis (PPV 60%; 47-73%), an

63 tical coherent tomography (iSD-OCT) assisted PPV using Rescan 700 (Carl Zeiss Meditech, Jena, Germany

64 s received preoperative IVB 5-10 days before PPV compared to 1-3 days for the treatment of PDR-relate

65 received IVB (2.5 mg/0.1 mL) 1-3 days before PPV, while Group B received IVB (2.5 mg/0.1 mL) 5-10 day

66 eceived IVB (2.5 mg/0.1 mL) 5-10 days before PPV.

67 The algorithm showed better PPV (76% (95% CI 67% to 83%) vs 48% (95% CI 40% to 55%))

68 The recall rate, biopsy PPV, and cancer detection rate were calculated.

69 nce between DM and DBT with regard to biopsy PPV (30.2% vs 23.8%, P = .21) or cancer detection rate p

70 Observed values for both PPV and NPV for HBAT-ST (33 patients) were 100%.

71 ort sensitivity was < 50% for eight AEs, but PPV was > 75% for six AEs.

72 all the cases with IOFBs that we removed by PPV, over 5 years (2009-2013).

73 Recall rate, CDR, PPV of positive screening result (PPV1), PPV of biopsy r

74 ascites (PPV 75%; 95% CI 63-86%), cirrhosis (PPV 60%; 47-73%), and gastrointestinal hemorrhage (PPV 6

75 low risk (score </=2, 43.1% of total cohort, PPV 0.24%), and those at intermediate risk (score 3-5, 5

76 iate risk (score 3-5, 52.1% of total cohort, PPV 1.46%).

77 an accuracy of 98.2% based on DESI MSI data (PPV 0.96, NVP 1, specificity 0.96, sensitivity 1).

78 on and cancer detection rates and decreasing PPVs, with less than 70% of radiologists within acceptab

79 an in vivo demonstration of fatal VAE during PPV to show that air can travel from the suprachoroidal

80 Early PPV for central non-RRD and retinal schisis with the use

81 le of prophylactic laser retinopexy or early PPV is unknown at this time.

82 For bacteremia caused by 3GC-R EB, PPVs of prior colonization with 3GC-R EB (90-day window)

83 y discharge diagnosis of 691.8 had excellent PPV.

84 Experimental PPV under general anesthesia was performed on porcine ey

85 47 logMAR VA [Snellen equivalent, 20/59] for PPV and 0.52 logMAR VA [Snellen equivalent, 20/66] for S

86 years (between 15 and 60), 27 M,9 F) of 23-G PPV for the removal of IOFBs during the period of April

87 23-Gauge PPV is a feasible, effective approach in the surgical ma

88 Eyes undergoing 27 gauge PPV for a vitreoretinal surgery indication.

89 The 27 gauge PPV was well tolerated with low rates of intraoperative

90 Three-port, transconjunctival 27 gauge PPV.

91 390 eyes of 360 patients undergoing 27-gauge PPV for a vitreoretinal surgery indication.

92 At a minimum follow-up of 1 year, 27-gauge PPV was well tolerated with low rates of postoperative c

93 Three-port, transconjunctival, 27-gauge PPV.

94 An IPF score offered the greatest PPV, but it requires further validation.

95 ed with injections alone, and 10 (14.5%) had PPV.

96 ed with injections alone, and 21 (18.9%) had PPV after 1 year.

97 s and scleritis/episcleritis ICD-9 codes had PPVs of 91% (95% CI, 86%-95%) and 60% (95% CI, 54%-66%),

98 %; 47-73%), and gastrointestinal hemorrhage (PPV 62%; 51-73%) had improved performance, however, the

99 To engineer heterotelechelic PPVs in a sheet-like design, we engineer an iterative on

100 ramolecular assembly of two heterotelechelic PPVs is used to realize a parallel pi-sheet, wherein fur

101 quently (<20 instances) but still had a high PPV (all 100%) and NPV (99.7%-100%) were codes for aflib

102 st that were used frequently also had a high PPV (range, 89.5%-100%) and NPV (88.6%-100%) including b

103 rage of 2 samples was needed to achieve high PPVs (range, 86%-100%) and NPVs (range, 91%-100%).

104 there were specific uveitis codes with high PPVs.

105 newly diagnosed breast cancer, with a higher PPV.

106 [69 of 70 lesions]), a significantly higher PPV than MR imaging (93% [66 of 71 lesions] vs 60% [69 o

107 nterim FLT PET/CT had a significantly higher PPV than standardized FDG PET/CT-based interpretation fo

108 Phacoemulsification with IOL implant, PPV with silicone oil tamponade associated with 180 degr

109 asthma, hay fever, and food allergy improves PPV and specificity.

110 orcine model confirms that during the FAE in PPV, pressurized air from an infusion cannula malpositio

111 was closer to that in PCV recipients than in PPV recipients.

112 nterest were additional treatments including PPV, injections, and panretinal photocoagulation (PRP),

113 Increased PPV was associated with concomitant diagnoses of asthma,

114 ography (PPV, 69.6%) and subtenon injection (PPV, 100%; NPV, 99.7%, but sensitivity of only 40%) were

115 r disorder on the basis of direct interview (PPV=1.0).

116 ngue with plasma than those without leakage (PPV, 88.1% vs 90.6% [P = .01]; MFI, 2.1 vs 2.4 [P = .007

117 V, 1.00; PPV, 0.62) had a high NPV but a low PPV.

118 h 3GC-R EB and prior antibiotic use have low PPV for infections caused by 3GC-R EB.

119 In conclusion the low PPV of the diagnosis code for AH suggests that caution i

120 1 sample alone resulted in high NPVs but low PPVs (range, 43%-91%).

121 3%), comparable NPV (89% and 90%-91%), lower PPV (23%-42% and 34%-60%), and lower AUC (0.68-0.73 and

122 sensitivity (> 50% for nine AEs), but lower PPV (< 75% for 10 AEs).

123 es using different polymers, i.e. F8BT, MDMO-PPV, PS, thus providing micrometric-sized taggants suita

124 methyloctyloxy)-1,4-phenylenevinylene] (MDMO-PPV), polystyrene (PS), thus breaking a new ground on th

125 For P3HT and MEH-PPV oligomers, the calculated intense absorption bands c

126 ntrast other conjugated polymers such as MEH-PPV where much slower intrachain energy transfer was rep

127 rm that the exciton spectral features in MEH-PPV overlap with those of the bipolaron formation.

128 2-ethylhexyloxy)-1,4-phenylenevinylene) (MEH-PPV), and poly(benzodithiophene-thieno[3,4-b]thiophene)

129 particles made of the conjugated polymer MEH-PPV can generate luminescence persisting for an hour upo

130 a vitrectomy (PPV) (hazard ratio [HR] [vs no PPV] = 2.39; 95% CI, 1.42-4.00), diagnosis of intermedia

131 Observed PPVs and NPVs of ST for other botulinum antitoxins (302

132 Also, the rate of PPV at 2 years (27.9%, n = 31) suggests that most patien

133 er experiments, supporting a contribution of PPVs to transition state formation.

134 ith a history of ocular surgery, the overall PPV for uveitis was 61% (95% CI, 56%-66%).

135 atients who underwent total PPVs and partial PPVs or AVs.

136 eous base (n = 22) and those who had partial PPVs or anterior vitrectomies (AVs) at the time of KPro

137 erative complications than eyes with partial PPVs or AVs during the average 4 years of follow-up.

138 (PPV), and combined scleral buckle (SB) plus PPV (SB+PPV).

139 D-9-CM codes 691.8 and 692.9 alone have poor PPV.

140 Positive (PPV) and negative predictive values (NPV) were calculate

141 DR, PPV of positive screening result (PPV1), PPV of biopsy recommendation (PPV2), and PPV of biopsies

142 Anatomic success rates for secondary PR, PPV, and SB+PPV after failed PR were lower than publishe

143 changeable (2)H (D) to perturb the predicted PPVs.

144 s classification methods for MCI prediction (PPV: 0.80 vs. 0.67, 0.63).

145 compared with eyes that underwent a primary PPV.

146 o evaluate the anatomical results of primary PPV for the treatment of primary complex RRD and to dete

147 this GWA study validated previously reported PPV resistance quantitative trait loci (QTL) intervals,

148 nts with PDR-related complications requiring PPV were prospectively randomized into 1 of 2 treatment

149 al aspects using poly(p-phenylenevinylene)s (PPVs).

150 s similar between eyes undergoing PPV and SB+PPV (0.47 logMAR VA [Snellen equivalent, 20/59] for PPV

151 s between repeat PR (63%), PPV (76%), and SB+PPV (88%).

152 success rates for secondary PR, PPV, and SB+PPV after failed PR were lower than published success ra

153 logMAR VA [Snellen equivalent, 20/66] for SB+PPV; P = 0.75).

154 nd combined scleral buckle (SB) plus PPV (SB+PPV).

155 t anatomic success rates are greater with SB+PPV than PPV and, in turn, with PPV than repeat PR.

156 This equation has a high specificity, PPV with a moderate NPV and sensitivity in perioperative

157 eview demonstrated sensitivity, specificity, PPV, and negative predictive value of 47.6%, 93.9%, 55.6

158 The accuracy, sensitivity, specificity, PPV, and NPV of MRI-based N-staging were 82.1%, 75%, 67.

159 le infections, the sensitivity, specificity, PPV, and NPV were 78.8%, 93.7%, 62.3%, and 97.1%.

160 The sextant-level sensitivity, specificity, PPV, NPV, and area under the receiver operating characte

161 The accuracy, sensitivity, specificity, PPV, NPV, and diagnostic time were compared among DNN-CA

162 d Abbott assays, but only 38 achieved SVR12 (PPV, 69%).

163 t an antiparallel pi-sheet, wherein terminal PPV blocks are adjacent to a flexible coil-like poly(nor

164 c success rates are greater with SB+PPV than PPV and, in turn, with PPV than repeat PR.

165 The PPV of bipolar disorder defined by natural language proc

166 The PPV was also low, requiring further investigation.

167 higher vCDR asymmetry cutoff of >/=0.30, the PPV increases to 37.7%.

168 , the NPV was 0.87 (95% CI: 0.69, 0.95), the PPV was 0.89 (95% CI: 0.69, 0.97), and the mean reading

169 confidence interval [CI], 98.61-99.99); the PPV was 100.00 (95% CI, 98.68-100.00) when only malabsor

170 5%-10.8%) were higher than predicted and the PPV was lower (42.1%; 95% CI, 41.3%-42.9%) than predicte

171 is predictive of prevalent glaucoma, but the PPV remains low even at high degrees of asymmetry.

172 nitored and recorded in real time during the PPV, including end-tidal carbon dioxide (ETCO2), oxygen

173 es change with prevalence to extrapolate the PPV and NPV to populations with lower prevalence of celi

174 period prevalences of IPF, corrected for the PPV, were 14.6 per 100,000 person-years and 58.7 per 100

175 Quantification of decoy cells improved the PPV to 32.1% (10 >/= cells threshold).

176 requently in the pneumonia group than in the PPV (P = .000) and PCV (P = .029) groups, L-selectin was

177 requently in the pneumonia group than in the PPV group (P = .001).

178 electin was expressed more frequently in the PPV group than in the PCV group (P = .014); and CLA was

179 antibodies and HLA type did not increase the PPV of samples with levels of IgA-TTG >/=10-fold the ULN

180 or all US findings, MR imaging increased the PPV from 12.9% (20 of 155 cases; 95% CI: 7.6%, 18.2%) to

181 o 6.7% (95% CI, 6.6%-6.8%) and increased the PPV to 49.1% (95% CI, 48.3%-49.9%).

182 Additional criteria increased the PPV up to 95% but would miss up to 89% of individuals wi

183 h an SVR4 also achieved an SVR12, making the PPV of SVR4 for SVR12 98% and the NPV 100%.

184 in the SB group and 19 (90%) patients of the PPV group achieved retinal reattachment.

185 For the IPF score, the PPV was 76.2%.

186 6%, respectively, and for the IPF score, the PPV was 83.3%.

187 r extrapolation model, we estimated that the PPV and NPV would remain >0.95 even at a disease prevale

188 The PPVs and NPVs ranged from 69.2% to 78.6% and from 86.1%

189 The PPVs for individual uveitis codes ranged from 0% to 100%

190 The PPVs were calculated by determining the ratio of the con

191 variants were analyzed using the HWA and the PPVs and NPVs for each gene were greater than 0.997 and

192 ng the clinical adjudicator's diagnosis, the PPVs were 54 and 57.6%, respectively, and for the IPF sc

193 After medical record review, the PPVs of these algorithms using the treating clinician's

194 Though PPV was 100% in the groups with HRCT alone, MR cisternog

195 rmeniaca) germplasm containing resistance to PPV, next-generation sequence-based genotyping, and the

196 erative complications was lower in the total PPV group (P = 0.018, log-rank test).

197 cations between patients who underwent total PPVs and partial PPVs or AVs.

198 Eyes that underwent total PPVs during implantation of aphakic, snap-on, type I Bos

199 In particular, eyes that underwent total PPVs had lower rates of retroprosthetic membranes (RPMs)

200 ompared between patients who underwent total PPVs with shaving of the vitreous base (n = 22) and thos

201 ue absence of follow-up in 75 cases (trigger PPV of 57.3% for detecting evaluation delays), of which

202 els of TGA-IgA were 10-fold or more the ULN, PPVs ranged from 99.63 (95% CI, 98.67-99.96) to 100.00 (

203 or infrequently used B-scan ultrasonography (PPV, 69.6%) and subtenon injection (PPV, 100%; NPV, 99.7

204 t 1 year was similar between eyes undergoing PPV and SB+PPV (0.47 logMAR VA [Snellen equivalent, 20/5

205 All eyes underwent PPV alone and complete drainage of subretinal fluid, wit

206 e hundred and twenty-five subjects underwent PPV and completed the 6-month follow-up interval.

207 All patients subsequently underwent PPV and silicone oil tamponade at our Institution.

208 ve complications, and incidence of unplanned PPV at 6 months follow-up.

209 ve complications, and incidence of unplanned PPV during the study interval.

210 ity, specificity, positive prediction value (PPV), and negative prediction value, we found no statist

211 and positive and negative predictive value (PPV and NPV) for the two Arabic CAM-ICU raters, where ca

212 nificantly higher positive predictive value (PPV) (91%) in predicting residual disease than did any F

213 ficity (Sp) 0.98, positive predictive value (PPV) 0.87, negative predictive value (NPV) 0.90, and acc

214 5% CI: 0.7, 0.8); positive predictive value (PPV) 1, 4.4% (95% CI: 4.3%, 4.5%); PPV2, 25.6% (95% CI:

215 ac disease with a positive predictive value (PPV) above 99% in clinical practice.

216 specificity, and positive predictive value (PPV) among females, 6 and 10 repeat samples for the high

217 ity, specificity, positive predictive value (PPV) and diagnostic OR of algorithmic and physician diag

218 ity, specificity, positive predictive value (PPV) and negative (N) PV of 78%, 91%, 98% and 44%, respe

219 The positive predictive value (PPV) and negative predictive value (NPV) for each code o

220 Positive predictive value (PPV) and negative predictive value (NPV) of HCV RNA less

221 We calculated the positive predictive value (PPV) and negative predictive value (NPV) of ST for anaph

222 uding the highest Positive Predictive Value (PPV) compared to the current state-of-the-art, as assess

223 specificity, and positive predictive value (PPV) for current medication use.

224 The positive predictive value (PPV) for rayon swabs was 78.7%, versus 83.5% for ESwabs.

225 The positive predictive value (PPV) for recall was almost doubled with DBT plus synthet

226 ing increased the positive predictive value (PPV) from 17.5% (21 of 120 cases; 95% confidence interva

227 io is 9.9 and the positive predictive value (PPV) is 7.0%.

228 ity of 0.40 and a positive predictive value (PPV) of 0.96 for heart failure identification.

229 city of 100%, and positive predictive value (PPV) of 100% for detecting causes of chest pain.

230 orresponding to a positive predictive value (PPV) of 54% (95% CI 47-60%).

231 -91% and 86%-89%, positive predictive value (PPV) of 60%-70% and 62%-75%, and area under the receiver

232 0% and 75%, and a positive predictive value (PPV) of 71% [95% confidence interval (CI 56%-84%)].

233 icity of 90.7%, a positive predictive value (PPV) of 74.0%, and a negative predictive value (NPV) of

234 % (98.6 to 99.7), positive predictive value (PPV) of 93.3% (86.8 to 97.3), and negative predictive va

235 vity of 93.7% and positive predictive value (PPV) of 96.7% when correlated with surgical findings.

236 I: 12.5%, 12.7%); positive predictive value (PPV) of a biopsy recommendation (PPV2), 27.5% (95% CI: 2

237 n outcome was the positive predictive value (PPV) of ICD-9 codes for identifying specific types of oc

238 s specificity and positive predictive value (PPV) of MR imaging screening.

239 curve (AUC), and positive predictive value (PPV) of the revised ASRS.

240 The positive predictive value (PPV) of the Xpert Norovirus assay was 75% for GI-positiv

241 f reactivity, 95% positive predictive value (PPV) or challenge, corrected for ancestry by principal c

242 ars that have 95% positive predictive value (PPV) or negative predictive value for the persistence or

243 and assess their positive predictive value (PPV) to estimate incidence and prevalence in the United

244 ecificity and 96% positive predictive value (PPV) using the original 2-level logistic classification

245 5, 0.99), and the positive predictive value (PPV) was 0.93 (95% CI: 0.75, 0.99).

246 dence of IMLN and positive predictive value (PPV) were calculated on a per-patient level by using pro

247 Sensitivity and positive predictive value (PPV) were determined for the test methods and the refere

248 5% CI: 86%, 98%); positive predictive value (PPV), 80% (95% CI: 59%, 93%); and negative predictive va

249 ity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of MALDI-TOF M

250 ity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of MRI-based T

251 ity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of RDTs were 5

252 ity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were all 100%.

253 ity, specificity, positive predictive value (PPV), and negative predictive value (NPV).

254 ity, specificity, positive predictive value (PPV), and negative predictive value (NPV).

255 ity, specificity, positive predictive value (PPV), and negative predictive value of 54.8%, 97.7%, 79.

256 ity, specificity, positive predictive value (PPV), and negative predictive value were calculated for

257 m 86% to 94%; and positive predictive value (PPV), from 3% to 8%.

258 ity, specificity, positive predictive value (PPV), negative predictive value (NPV) and diagnostic acc

259 ity, specificity, positive predictive value (PPV), negative predictive value (NPV), and Cohen's kappa

260 ity, specificity, positive predictive value (PPV), negative predictive value (NPV), and diagnostic ti

261 ity, specificity, positive predictive value (PPV), negative predictive value (NPV), and positive like

262 ecificity and 93% positive predictive value (PPV).

263 cts RIF with 100% positive predictive value (PPV).

264 ) and the highest positive predictive value (PPV; 96.1%) for a random sample of previously validated

265 of total cohort, positive predictive value [PPV] 11.7%), those at low risk (score </=2, 43.1% of tot

266 ity, specificity, positive predictive value [PPV] and negative predictive value [NPV] of both MR cist

267 [95% CI, 62-68]; positive predictive value [PPV], 24 [95% CI, 16-32]; negative predictive value [NPV

268 sistant isolates (positive predictive value [PPV], 78%).

269 ity, specificity, positive predictive value [PPV], and negative predictive value [NPV]; treatment eff

270 the positive and negative predictive values (PPV and NPV) of these diagnostic procedures.

271 he incidence and positive predictive values (PPV) of C4d-CD68 and pAMR grades for clinical AMR as a f

272 sensitivity and positive predictive values (PPV) of the AAML0531 AE report and AEs detected by revie

273 specificity, and positive predictive values (PPV) of the codes were calculated.

274 , specificities, positive predictive values (PPV), and negative predictive values (NPV) were 92.7%, 1

275 resulted in low positive predictive values (PPVs) and false-positive rates, with a lack of precision

276 We calculated positive predictive values (PPVs) and negative predictive values (NPVs) by comparing

277 est results, and positive predictive values (PPVs) for advanced neoplasia were determined weekly, qua

278 rate (CDR), and positive predictive values (PPVs) for digital mammography before and after radiologi

279 Positive predictive values (PPVs) of these determinants are unknown.

280 urves [AUCs] and positive predictive values [PPVs].

281 The proportion of perfused vessels (PPV) and the mean flow index (MFI) were lower in patient

282 (LDH) employs protein promoting vibrations (PPVs) on the femtosecond (fs) to picosecond (ps) time sc

283 To address this problem for Plum Pox Virus (PPV) candidate resistance gene identification in Prunus

284 the impact of total pars plana vitrectomies (PPVs) with peripheral shaving of the vitreous base on th

285 ission included prior pars plana vitrectomy (PPV) (hazard ratio [HR] [vs no PPV] = 2.39; 95% CI, 1.42

286 ses were treated with pars plana vitrectomy (PPV) and a double silicone oil endotamponade (DSOE) of b

287 betic eyes undergoing pars plana vitrectomy (PPV) and silicone oil tamponade with or without scleral

288 embolism (VAE) during pars plana vitrectomy (PPV) can occur owing to improper positioning of the infu

289 iOCT) in all steps of pars plana vitrectomy (PPV) for non-RRD in MGS, in order to follow pathophysiol

290 ulation (PRP), or (3) pars plana vitrectomy (PPV) for PDR; and study eye changes on the DRSS.

291 c subjects undergoing pars plana vitrectomy (PPV) for severe manifestations of active proliferative d

292 outcomes of 27-gauge pars plana vitrectomy (PPV) in eyes with posterior segment disease.

293 lactic laser or early pars plana vitrectomy (PPV) in preventing retinal detachment (RD) remains uncle

294 Pars plana vitrectomy (PPV) is preferred surgical procedure for the management

295 including repeat PR, pars plana vitrectomy (PPV), and combined scleral buckle (SB) plus PPV (SB+PPV)

296 e study, a history of pars plana vitrectomy (PPV), and less than 1 year of follow-up.

297 antifungal injection, pars plana vitrectomy (PPV).

298 ty-six eyes underwent pars plana vitrectomy (PPV).

299 Eyes managed with PPV and removal of the IOL and capsular bag had better v

300 m 117 patients with complex RRD managed with PPV.

301 ater with SB+PPV than PPV and, in turn, with PPV than repeat PR.